Unknown

Dataset Information

0

CRISPR screens are feasible in TP53 wild-type cells.

ABSTRACT: A recent study by Haapaniemi et al (2018) reported that intact p53 signaling hampers CRISPR-based functional genomic screens. Brown et al report good performance of genome-scale screens in TP53 wild-type cells and reiterate best practices for CRISPR screening.

SUBMITTER: Brown KR 

PROVIDER: S-EPMC6686785 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

CRISPR screens are feasible in TP53 wild-type cells.

Brown Kevin R KR   Mair Barbara B   Soste Martin M   Moffat Jason J  

Molecular systems biology 20190801 8

A recent study by Haapaniemi et al (2018) reported that intact p53 signaling hampers CRISPR-based functional genomic screens. Brown et al report good performance of genome-scale screens in TP53 wild-type cells and reiterate best practices for CRISPR screening. ...[more]

Similar Datasets

Unknown Reply to "CRISPR screens are feasible in TP53 wild-type cells".
| S-EPMC6686827 | biostudies-other
Other CRISPR screens are feasible in TP53 wild-type cells
2019-04-30 | GSE128210 | GEO
Genomics CRISPR screens are feasible in TP53 wild-type cells
| PRJNA526806 | ENA
Unknown Genome-scale CRISPR-Cas9 screen identifies druggable dependencies in <i>TP53</i> wild-type Ewing sarcoma.
| S-EPMC6080915 | biostudies-literature
Genomics Keratinocyte CRISPR screens
| EGAS00001002714 | EGA
Unknown Kevetrin induces apoptosis in TP53 wild?type and mutant acute myeloid leukemia cells.
| S-EPMC7448420 | biostudies-literature
Unknown Poor survival with wild-type TP53 ovarian cancer?
| S-EPMC4059202 | biostudies-literature
Proteomics nascent proteome analysis of HCT116 TP53 wild type and TP53 knockout cells treated with Neocarcinostatin (NCS) for 6h
2022-04-27 | PXD029512 | Pride
Unknown Expression signature based on TP53 target genes doesn't predict response to TP53-MDM2 inhibitor in wild type TP53 tumors.
| S-EPMC4728122 | biostudies-literature
Unknown Genetic screens in human cells using the CRISPR-Cas9 system.
| S-EPMC3972032 | biostudies-literature